Table 1.
Clinical characteristics of IgAN–MN patients, IgAN patients and MN patients.
| Characteristics | IgA–MN | IgAN | MN | p (IgAN–MN vs. IgAN) | p (IgAN–MN vs. MN) |
|---|---|---|---|---|---|
| Number of patients | 26 | 52 | 52 | ||
| Baseline characteristics | |||||
| Gender (male) | 17 (65.4) | 25 (48.1) | 30 (57.7) | .148 | .513 |
| Age (years) | 43.6 ± 15.9 | 34.9 ± 11.1 | 51.4 ± 13.3 | .017 | .026 |
| Gross hematuria | 3 (11.5) | 16 (30.7) | 0 (0) | .056 | .061 |
| Hypertension | 7 (26.9) | 18 (34.6) | 15 (28.8) | .493 | .859 |
| Initial proteinuria (g/day) | 4.3 (2.4, 6.3) | 1.2 (0.7, 1.9) | 5.1 (3.1, 7.1) | <.001 | .455 |
| eGFR (mL/min/1.73 m2) | 101.8 ± 25.4 | 78.5 ± 26.9 | 100.2 ± 21.6 | <.001 | .778 |
| Nephrotic syndrome | 16 (61.5) | 32 (61.5) | 33 (63.5) | <.001 | .868 |
| Therapy | |||||
| ACE inhibitors or ARBs | 16 (61.5) | 51 (98.1) | 29 (55.8) | <.001 | .627 |
| Glucocorticoids | 15 (57.7) | 26 (50.0) | 38 (73.1) | .521 | .170 |
| Any other immunosuppressive agents | 11 (42.3) | 16 (30.8) | 38 (73.1) | .313 | .008 |
| Follow-upa | |||||
| Follow-up interval (months) | 22.8 (10.1, 81.4) | 82.3 (47.8, 114.7) | 37.4 (24.6, 69.6) | <.001 | .053 |
| Kidney progression eventb | 2 (10.5) | 8 (15.4) | 3 (6.1) | .892 | .865 |
| Partial remission and complete remissionc | 14 (73.7) | – | 39 (75.0) | – | .845 |
eGFR: estimated glomerular filtration rate.
Values were presented as n (%) for number (%), mean ± standard for continuous, median (25–75% interquartile) for non-normally distributed continuous variables.
aFollow-up data were available only in 19 of the 26 patients with combined IgAN–MN.
bKidney progression event was defined as eGFR decreasing by half, or end-stage renal disease.
cPartial remission was defined as proteinuria <3.5 g/day plus a 50% reduction from its peak value; complete remission was defined as proteinuria <0.3 g/day.